Loading data for HCM — first visit, this takes a few seconds.

Alert

HUTCHMED (China) Limited (HCM)

NasdaqGS: HCM · Real-Time Price · USD

12.63

+0.07 (0.56%)

At close: Aug 26, 2026, 8:00 PM

12.36

+0.08%

Pre-market: 4:20 AM

The price, the headline numbers and the latest news, in one place.

0.56% (1D)

No data available

Bid	9.11
Market Cap	2.15B
Revenue (ttm)	549.12M
Net Income (ttm)	17.88M
	0.44
	0.1
	123.5
	50.65
P/B (ttm)	1.70
P/S (ttm)	3.91
Earnings Date	Jul 30, 2017

Ask	16.08
Volume	50,302
Avg. Volume (20D)	57,909
Open	12.56
Previous Close	12.56
Day's Range	12.56 - 12.70
52-Week Range	9.77 - 18.30
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About HCM

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-C...

Sector Healthcare

IPO Date Mar 16, 2016

Employees 1,790

Stock Exchange NasdaqGS

Ticker Symbol HCM

Website https://www.hutch-med.com

Full Company Profile

Financial Performance

In 2025, HUTCHMED (China)'s revenue was 548.51M, a decrease of -12.96% compared to the previous year's 630.2M. Earnings were 456.91M, an increase of 1,111.03%.

Financial Statements

Earnings Surprise

HUTCHMED (China) has released their quarterly earnings on Mar 2, 2022:

Revenue of n/a misses estimates by $0, with NaN% YoY growth.
EPS of -0.03 exceeds estimates by 0.10, with 0.00% YoY growth.

Next Earnings Release

HUTCHMED (China) Limited is scheduled to release its earnings on Jul 30, 2017, after market closes.
Analysts project revenue of ... Upgrade

News

1 week ago · Proactive

HUTCHMED shares rise as lung cancer drug trial hits key targets

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung ...

3 weeks ago · GuruFocus.com

HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and ...

HUTCHMED (China) Ltd (HCM) reports robust China product sales and global expansion, while advancing its novel ATTC pipeline and maintaining a profitable outlook.

3 weeks ago · MarketBeat

HUTCHMED H1 Earnings Call Highlights

HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported r...

2 months ago · Insider Monkey

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks. TheFly reported on May 28 that Mo...

4 months ago · MarketBeat

HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference

HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at th...

Page 1 of 2

HUTCHMED (China) Limited (HCM)